The Safety and Efficacy of ZVS106e in the Treatment of IRDs Caused by Biallelic Mutations in ABCA4 (ZVS106e)

A Preliminary Clinical Study on the Safety and Efficacy of the Gene Replacement Drug ZVS106e in the Treatment of Hereditary Retinal Degeneration (IRDs) Caused by ABCA4 Biallelic Mutations

To evaluate the preliminary safety of monocular and single subretinal injection of ZVS106e injection in the treatment of patients with hereditary retinal degeneration (ABCA4-IRDS) caused by ABCA4 biallelic mutations.

Study Overview

• Status: Recruiting
• Conditions: Stargardt
• Intervention / Treatment: Drug: ZVS106e

Detailed Description

The main research objective: To evaluate the preliminary safety of single subretinal injection of ZVS106e injection in one eye for patients with hereditary retinal degeneration (ABCA4-IRDS) caused by biallelic mutations in ABCA4. Secondary research objective: To preliminarily explore the clinical efficacy of ZVS106e injection in the treatment of patients with hereditary retinal degeneration (ABCA4-IRDS) caused by ABCA4 biallelic mutations. The purpose of the exploratory study is to evaluate the improvement of retinal structure and visual function in non-injection eyes compared to the baseline.

• Study Type: Interventional
• Enrollment (Estimated): 9
• Phase: Early Phase 1

Contacts and Locations

• Study Contact: Name: dayou Ding; Phone Number: 010-82266699; Email: dingdayou@chinagene.cc

Study Locations

• China
  • Beijing Municipality
    • Beijing, Beijing Municipality, China
      • Recruiting
      • Peking University Third Hospital
      • Contact: Jinlu Zhang, MD; Phone Number: +86-15810570898; Email: zhangjinlu@chinagene.cc
  • Guangdong
    • Guangzhou, Guangdong, China
      • Not yet recruiting
      • Zhongshan Ophthalmic Center, Sun Yat-sen University
      • Contact: Jinlu Zhang, MD; Phone Number: +86-15810570898; Email: zhangjinlu@chinagene.cc

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Age ≥8 years old;
2. Patients diagnosed with hereditary retinal degeneration caused by ABCA4 biallelic mutations through genetic testing, and without other ophthalmic genetic diseases;
3. The target eye must meet the following requirements: the best corrected visual acuity is 0.5 to 2.0 LogMAR (including 0.5 and 2.0 LogMAR, equivalent to the decimal visual acuity index up to 0.3);
4. The subject and his or her spouse agree to take effective contraceptive measures during the trial period and for at least one year after administration.
5. Voluntarily participate in clinical trials and sign informed consent forms, and be able to complete all trial processes as required by the protocol.

Exclusion Criteria:

1. The researchers determined that the target eye currently has or has previously had other macular lesions such as retinal schisis or epiretinal membrane. Or have other eye diseases that may hinder the surgery or interfere with the interpretation of the study endpoint;
2. Having received drug treatment that may affect the observation of the trial within the three months prior to screening;
3. The target eye has undergone the following intraocular surgeries: retinal repositioning and vitrectomy;
4. There are known eye/visual diseases, disorders or lesions that cause or are related to vision loss, or whose related treatments or therapies are known to cause or are related to vision loss;
5. Having suffered from a viral infectious disease that may affect the efficacy and safety evaluation of the investigational drug or having received an antiviral vaccine within one month prior to enrollment;
6. Systemic medications that are currently in use or may be required to cause eye toxicity, such as psoralen, risselinic acid or tamoxifen, etc.
7. Known to be allergic to the drugs planned to be used in the study;
8. Suffering from poorly drug-controlled hypertension: systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg;

9. The following laboratory test abnormalities have clinical significance:

   Liver function: Chronic liver disease, elevation of ALT or AST >2 times the upper limit of the normal value; Those with abnormal coagulation function (prothrombin time ≥ 3 seconds above the upper limit of the normal value, activated partial thromboplastin time ≥ 10 seconds above the upper limit of the normal value); Serum virological examination: Positive for active hepatitis B, hepatitis C virus antibody (HCV-Ab), human immunodeficiency virus antibody (HIV-Ab), or syphilis antibody;

10. There is any past or current medical history that may affect the safety of the trial or the in vivo process of the drug, especially a history of diseases such as cardiovascular, liver, kidney, endocrine, digestive tract, lung, nervous, hematological, tumor, immune or metabolic disorders that the investigators consider to have clinical significance;
11. Those who have participated in any clinical trials of drugs or medical devices within the three months prior to screening;
12. Pregnant or lactating women; According to the researcher's judgment, those who are deemed unsuitable to participate in this clinical trial for other reasons

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Single arm; All patients enrolled in the study will receive a single subretinal injection of ZVS106e in one eye	Drug: ZVS106e; ZVS106e is A colorless, clear and transparent liquid, containing two active ingredients, ZVS106E-A and ZVS106E-B. The viral vectors used for both active ingredients are rAAV8; Other Names: rAAV8

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluate the safety and tolerability of subretinal injection of ZVS106e solution	Types, severity, and incidence of adverse events (AE) and serious adverse events (SAE) in the eyes and throughout the body within 52 weeks post-treatment, including dose-limiting toxicities (DLT) during the dose escalation phase.	52 weeks post-treatment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline in best-corrected visual acuity (BCVA)	Change in best-corrected visual acuity (BCVA) of the treated eye at 52 weeks compared to baseline.	52 weeks post-treatment
Change from Baseline in Visual function metrics	Treatment outcomes for visual function metrics include changes from baseline in LLVA, dynamic visual field, microperimetry, FST, contrast sensitivity, color vision, and mfERG; as well as changes from baseline in the NEI-VFQ-25 score reported by the participants.	52 weeks post-treatment
Change from Baseline in OCT	Compare changes in retinal morphology and alterations in cell layers of the retina before and after drug administration.	52 weeks post-treatment
Change from Baseline in Fundus autofluorescence (FAF)	Compare the atrophy of the RPE/ photoreceptor complex in the subjects before and after administration	52 weeks post-treatment

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from Baseline in Michigan Retinal Degeneration Questionnaire (MRDQ)	Compare the improvement effects of vision-related anxiety in patients before and after administration	52 weeks post-treatment
Change from Baseline in multiluminance shape discrimination test (MLSDT) score	The improvement of the recognition ability for objects of different sizes under different brightness conditions before and after administration was compared. The higher the score, the stronger the shape recognition ability	52 weeks post-treatment

Collaborators and Investigators

• Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University
• Collaborators: Chigenovo Co., Ltd
• Investigators: Study Director: qingjiong zhang, M.D, PI; Principal Investigator: lin Lv, M.D, PI

Study record dates

Study Major Dates

• Study Start (Actual): December 29, 2025
• Primary Completion (Estimated): November 30, 2028
• Study Completion (Estimated): December 30, 2028

Study Registration Dates

• First Submitted: September 29, 2025
• First Submitted That Met QC Criteria: November 19, 2025
• First Posted (Actual): November 21, 2025

Study Record Updates

• Last Update Posted (Actual): April 16, 2026
• Last Update Submitted That Met QC Criteria: April 13, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: ZVS106e
• Other Study ID Numbers: ZYA-2025-002

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No